港股上市公司君实生物（01877）今日盘中大涨5.11%，引起市场广泛关注。截至上午10时38分，该股报价26.50港元左右。
此次股价上涨主要受到公司发布的2025年前三季度财报推动。根据公告，君实生物前三季度营业收入达18.06亿元人民币，同比增长42.06%。值得注意的是，公司归属于上市公司股东的净亏损同比收窄35.7%，降至5.96亿元人民币。这一业绩改善主要得益于公司核心产品特瑞普利单抗注射液（商品名：拓益®）在国内市场的强劲表现，该产品实现销售收入约14.95亿元人民币，同比增长约40%。
君实生物表示，公司正持续落实"提质增效重回报"行动方案，加强费用管控与资源聚焦，使得亏损金额显著缩窄。截至报告期末，公司拥有32.70亿元人民币的货币资金及交易性金融资产，显示出充足的资金储备。这些积极因素共同推动了投资者信心，带动股价上涨。市场分析人士认为，随着公司业务持续改善和核心产品销售增长，君实生物未来发展前景值得期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.